Dog Aging Project founders on what lies ahead after losing funding

CelebratingabirthdayatHappyBarkDay,thefirstdogcafeintheGulfemirateofDubai.KARIMSAHIB/AFPviaGettyImag Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor




knowledge

author：explore    Page View：48
Darron Cummings/AP

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

advertisement

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： California wildfire smoke linked to 52,000 early deaths, study says
Next article： Hepatitis C has a cure — but many Americans still lack access to it